Estella M Alonso1, Laura P James, Song Zhang, Robert H Squires. 1. *Department of Pediatrics, Northwestern Feinberg School of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL †Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Hospital Research Institute, Little Rock ‡Department of Epidemiology, University of Pittsburgh Graduate School of Public Health §Department of Pediatrics, University of Pittsburgh School of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Pittsburgh of UPMC, Pittsburgh.
Abstract
OBJECTIVES: Previous studies in patients with acute liver failure identified acetaminophen (APAP) protein adducts in the serum of 12% and 19% of children and adults, respectively, with acute liver failure of indeterminate etiology. This article details the testing of APAP adducts in a subset (n = 393) of patients with varied diagnoses in the Pediatric Acute Liver Failure Study Group (PALFSG). METHODS: Serum samples were available from 393 participants included in the PALFSG registry. Adduct measurement was performed using validated methods. Participants were grouped by diagnostic category as known APAP overdose, known other diagnosis, and indeterminate etiology. Demographic and clinical characteristics and participant outcomes were compared by adduct status (positive or negative) within each group. RESULTS: APAP adduct testing was positive in 86% of participants with known APAP overdose, 6% with other known diagnoses, and 11% with an indeterminate cause of liver failure. Adduct-positive participants were noted to have marked elevation of serum alanine aminotransferase and aspartate aminotransferase coupled with total serum bilirubin that was significantly lower than adduct-negative patients. In the indeterminate group, adduct-positive patients had different outcomes than adduct-negative patients (P = 0.03); spontaneous survival was 16 of 21 (76%) in adduct-positive patients versus 75 of 169 (44%) in adduct-negative patients. Prognosis did not vary by adduct status in patients with known diagnoses. CONCLUSIONS: Furthermore, study is needed to understand the relation of APAP exposure, as determined by the presence of APAP adducts, to the clinical phenotype and outcomes of children with acute liver failure.
OBJECTIVES: Previous studies in patients with acute liver failure identified acetaminophen (APAP) protein adducts in the serum of 12% and 19% of children and adults, respectively, with acute liver failure of indeterminate etiology. This article details the testing of APAP adducts in a subset (n = 393) of patients with varied diagnoses in the Pediatric Acute Liver Failure Study Group (PALFSG). METHODS: Serum samples were available from 393 participants included in the PALFSG registry. Adduct measurement was performed using validated methods. Participants were grouped by diagnostic category as known APAP overdose, known other diagnosis, and indeterminate etiology. Demographic and clinical characteristics and participant outcomes were compared by adduct status (positive or negative) within each group. RESULTS:APAP adduct testing was positive in 86% of participants with known APAP overdose, 6% with other known diagnoses, and 11% with an indeterminate cause of liver failure. Adduct-positive participants were noted to have marked elevation of serum alanine aminotransferase and aspartate aminotransferase coupled with total serum bilirubin that was significantly lower than adduct-negative patients. In the indeterminate group, adduct-positive patients had different outcomes than adduct-negative patients (P = 0.03); spontaneous survival was 16 of 21 (76%) in adduct-positive patients versus 75 of 169 (44%) in adduct-negative patients. Prognosis did not vary by adduct status in patients with known diagnoses. CONCLUSIONS: Furthermore, study is needed to understand the relation of APAP exposure, as determined by the presence of APAP adducts, to the clinical phenotype and outcomes of children with acute liver failure.
Authors: Laura P James; Estella M Alonso; Linda S Hynan; Jack A Hinson; Timothy J Davern; William M Lee; Robert H Squires Journal: Pediatrics Date: 2006-09 Impact factor: 7.124
Authors: L P James; E V Capparelli; P M Simpson; L Letzig; D Roberts; J A Hinson; G L Kearns; J L Blumer; J E Sullivan Journal: Clin Pharmacol Ther Date: 2008-10-15 Impact factor: 6.875
Authors: Robert H Squires; Anil Dhawan; Estella Alonso; Michael R Narkewicz; Benjamin L Shneider; Norberto Rodriguez-Baez; Dominic Dell Olio; Saul Karpen; John Bucuvalas; Steven Lobritto; Elizabeth Rand; Philip Rosenthal; Simon Horslen; Vicky Ng; Girish Subbarao; Nanda Kerkar; David Rudnick; M James Lopez; Kathleen Schwarz; Rene Romero; Scott Elisofon; Edward Doo; Patricia R Robuck; Sharon Lawlor; Steven H Belle Journal: Hepatology Date: 2013-02-04 Impact factor: 17.425
Authors: Michael R Narkewicz; Dominic Dell Olio; Saul J Karpen; Karen F Murray; Kathy Schwarz; Nada Yazigi; Song Zhang; Steven H Belle; Robert H Squires Journal: J Pediatr Date: 2009-07-29 Impact factor: 4.406
Authors: Laura P James; Lynda Letzig; Pippa M Simpson; Edmund Capparelli; Dean W Roberts; Jack A Hinson; Timothy J Davern; William M Lee Journal: Drug Metab Dispos Date: 2009-05-13 Impact factor: 3.922
Authors: Dean W Roberts; William M Lee; Jack A Hinson; Shasha Bai; Christopher J Swearingen; R Todd Stravitz; Adrian Reuben; Lynda Letzig; Pippa M Simpson; Jody Rule; Robert J Fontana; Daniel Ganger; K Rajender Reddy; Iris Liou; Oren Fix; Laura P James Journal: Clin Gastroenterol Hepatol Date: 2016-09-15 Impact factor: 11.382
Authors: Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane Journal: J Toxicol Environ Health A Date: 2017-09-11
Authors: Laura K Schnackenberg; Jinchun Sun; Sudeepa Bhattacharyya; Pritmohinder Gill; Laura P James; Richard D Beger Journal: Metabolites Date: 2017-09-06
Authors: Ruben Zamora; Derek Barclay; Jinling Yin; Estella M Alonso; Mike A Leonis; Qi Mi; Timothy R Billiar; Richard L Simmons; Robert H Squires; Yoram Vodovotz Journal: Sci Rep Date: 2019-04-12 Impact factor: 4.379
Authors: Sibo Jiang; Valvanera Vozmediano; Susan M Abdel-Rahman; Stephan Schmidt; Laura P James Journal: J Clin Pharmacol Date: 2019-05-17 Impact factor: 3.126